Results of phase II/III trial suggest that Bevacizumab/Pemetrexed/Cisplatin is a new treatment option although increased toxicity is a potential concern
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.
Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.
AZD9291, a third-generation irreversible EGFR tyrosine kinase inhibitor, demonstrated an ORR of 73% with few grade ≥ 3 adverse events in previously untreated patients with EGFR mutation–positive, advanced NSCLC.
Rociletinib, a third-generation EGFR TKI, is active in patients with acquired resistance to previous EGFR TKI therapy as detected by either standard tumor tissue biopsy or a plasma-based assay.
Phase II study results suggest dabrafenib plus trametinib have meaningful antitumor activity, manageable safety profile in BRAF V600E–mutated NSCLC.
Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.
In an interim analysis of atezolizumab as second-line or third-line therapy for advanced NSCLC, clinical efficacy correlated with PD-L1 expression level.
Early results from this phase I trial indicate a manageable safety profile along with robust, durable activity with pembrolizumab + ipilimumab in previously treated patients with advanced NSCLC.
Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.
Naiyer Rizvi, MD, and Heather Wakelee, MD, provide their analysis of key lung cancer presentations from the 2015 clinical oncology meeting in Chicago.
In this downloadable slideset of lung cancer clinical trial highlights from the 2015 American Society of Clinical Oncology annual meeting, Naiyer Rizvi, MD, and Heather Wakelee, MD, discuss key immunotherapy studies in NSCLC and SCLC, review targeting of driver mutations, and discuss treatment of mesothelioma.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.